<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04732598</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG1919E</org_study_id>
    <nct_id>NCT04732598</nct_id>
  </id_info>
  <brief_title>A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer</brief_title>
  <acronym>AMBITION</acronym>
  <official_title>A Phase III, Randomized Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Patients With Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japanese Foundation for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Japanese Foundation for Cancer Research</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JCOG1919E (AMBITION) is a randomized, open-label, phase 3 trial to evaluate efficacy and&#xD;
      safety of bevacizumab and paclitaxel in combination with atezolizumab comparing to&#xD;
      bevacizumab and paclitaxel in patients with HR-positive HER2 negative metastatic breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (investigator-assessed)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (blinded independent central review)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (investigator-assessed)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (investigator-assessed)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (blinded independent central review)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (blinded independent central review)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of immune-related adverse events</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in PD-L1 positive subpopulation (investigator-assessed)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD- L1-positive subpopulation</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival in the PD-L1-positive subpopulation (investigator-assessed)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival in the PD-L1-positive subpopulation</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in the PD-L1-positive subpopulation (investigator-assessed)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate in the PD-L1-positive subpopulation (blinded independent central review)</measure>
    <time_frame>Up to 2years after last patient enrolled</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + bevacizumab therapy</intervention_name>
    <description>The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.&#xD;
[Paclitaxel] 90mg/m^2, day1,8,15, IV [Bevacizumab] 10mg/kg, day1,15, IV</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + bevacizumab + atezolizumab</intervention_name>
    <description>The following regimen will be continued as a 28-day course until disease progression or the criteria for treatment discontinuation are met.&#xD;
[Atezolizumab] 840 mg/body, day 1,15, IV [Paclitaxel] 90mg/m^2, day1,8,15, IV [Bevacizumab] 10mg/kg, day1,15, IV</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically diagnosed as breast cancer (invasive cancer).&#xD;
&#xD;
          -  Histologically diagnosed as hormone receptor positive (at least one of ER and PgR is&#xD;
             positive) and HER2 negative. However, if there are multiple specimens, the&#xD;
             histological results of the most recent specimen that meets the eligibility criteria&#xD;
             (1) and (2) should be used.&#xD;
&#xD;
          -  Diagnosed with advanced recurrent breast cancer (either unresectable locally advanced&#xD;
             breast cancer, recurrent breast cancer, or Stage IV breast cancer).&#xD;
&#xD;
          -  Age 20 years or older on the date of registration. Either male or female are&#xD;
             acceptable.&#xD;
&#xD;
          -  ECOG performance status (PS) of 0-2.&#xD;
&#xD;
          -  Patients must have measurable lesions.&#xD;
&#xD;
          -  Hormone refractory[*1] or life-threatening metastases [*2].&#xD;
&#xD;
               1. Hormone refractory: Recurrence within 2 years after the start of postoperative&#xD;
                  endocrine therapy, or progression within 6 months of endocrine therapy for&#xD;
                  advanced recurrent breast cancer.&#xD;
&#xD;
               2. Life-threatening metastases: Symptomatic metastases that require symptomatic&#xD;
                  relief through urgent tumor shrinkage. Examples include multiple liver&#xD;
                  metastases, lung metastases, carcinomatous pleurisy, and carcinomatous&#xD;
                  lymphangitis.&#xD;
&#xD;
          -  PD-L1 status has been confirmed by a central measurement institute.&#xD;
&#xD;
          -  No active brain metastases that require treatment.&#xD;
&#xD;
          -  No history of prior chemotherapy treatment for advanced or recurrent breast cancer.&#xD;
             However, in case that a history of preoperative/postoperative chemotherapy including&#xD;
             paclitaxel or docetaxel, it is acceptable if at least 6 months have passed since the&#xD;
             last dose.&#xD;
&#xD;
          -  The most recent laboratory test within 14 days prior to enrollment (the same day of&#xD;
             the week two weeks prior to the date of enrollment is acceptable) must meet all of the&#xD;
             following&#xD;
&#xD;
               1. Neutrophil count ≥1,500/mm^3&#xD;
&#xD;
               2. Hemoglobin ≥ 9.0 g/dL (No blood transfusion within 14 days prior to the date of&#xD;
                  blood collection for the test used for registration)&#xD;
&#xD;
               3. Platelet count ≥10×104/mm^3&#xD;
&#xD;
               4. Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
               5. AST ≤ 100 IU/L (≤ 150 IU/L if liver metastasis is present)&#xD;
&#xD;
               6. ALT ≤ 100 IU/L (≤ 150 IU/L in case of liver metastasis)&#xD;
&#xD;
               7. Serum creatinine ≤1.2 mg/dL&#xD;
&#xD;
               8. PT-INR ≤ 1.5, but PT-INR ≤ 3.0 if the patient is taking anticoagulants such as&#xD;
                  warfarin prophylactically.&#xD;
&#xD;
               9. Urine protein (test paper method) of 1+ or less&#xD;
&#xD;
          -  For women of childbearing potential [*1], consent for contraception from the time of&#xD;
             obtaining consent until at least 6 months after completion of the protocol treatment.&#xD;
             For lactating patients, the patient agrees not to breastfeed from the start of&#xD;
             protocol treatment until at least 6 months after the end of protocol treatment. For&#xD;
             men, they agree to use contraception from the start of protocol treatment until at&#xD;
             least 6 months after the end of protocol treatment [*2].&#xD;
&#xD;
               1. Women of childbearing potential: Women who have experienced menarche, have not&#xD;
                  undergone sterilization (hysterectomy or bilateral oophorectomy), and have not&#xD;
                  undergone menopause. Menopause is defined as the absence of menstruation for more&#xD;
                  than 12 months without another medical reason such as drug administration.&#xD;
&#xD;
               2. Examples of contraceptive methods: condoms, pessaries, oral contraceptives, use&#xD;
                  of intrauterine devices, etc.&#xD;
&#xD;
          -  The patient's written consent to participate in the study has been obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active multiple cancer. However, the following are excluded: ①Completely resected&#xD;
             cancers: basal cell carcinoma, Stage I spinous cell carcinoma, intraepithelial&#xD;
             carcinoma, intramucosal carcinoma, superficial bladder cancer, ② gastrointestinal&#xD;
             tract cancer that has been curatively resected by ESD or EMR, and ③ other cancers that&#xD;
             have not recurred for more than 5 years.&#xD;
&#xD;
          -  Infectious diseases that require systemic treatment.&#xD;
&#xD;
          -  Complicated active gastrointestinal ulcer.&#xD;
&#xD;
          -  Patients must have poorly controlled hypertension (systolic blood pressure ≥150 mmHg&#xD;
             and/or diastolic blood pressure ≥100 mmHg) despite the use of two or more&#xD;
             antihypertensive agents.&#xD;
&#xD;
          -  Patients must have symptomatic congestive heart failure, unstable angina, or&#xD;
             arrhythmia requiring treatment at the time of enrollment.&#xD;
&#xD;
          -  History of myocardial infarction within 1 year prior to enrollment.&#xD;
&#xD;
          -  Major surgery or incisional biopsy or significant trauma within 28 days prior to&#xD;
             enrollment; placement of a CV port is not considered major surgery.&#xD;
&#xD;
          -  Patients with deep vein thrombosis or pulmonary embolism at the time of enrollment, or&#xD;
             a history of such within 1 year prior to enrollment.&#xD;
&#xD;
          -  Use of anticoagulants (except aspirin of 324 mg/day or less) within 10 days prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Patients with a history of idiopathic pulmonary fibrosis, organizing pneumonia&#xD;
             (bronchiolitis obliterans, etc.), drug-induced pneumonitis, or idiopathic pneumonitis.&#xD;
             However, patients with a history of drug-induced pneumonitis who are asymptomatic at&#xD;
             the time of enrollment can be enrolled if they undergo regular chest X-ray&#xD;
             examinations and careful follow-up including auscultation and medical examination.&#xD;
&#xD;
          -  Findings of active pneumocystitis on chest CT. However, a history of localized&#xD;
             radiation pneumonitis (fibrosis) in the irradiation field is inclusible.&#xD;
&#xD;
          -  Patients have been treated with investigational atezolizumab, or other immune&#xD;
             checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody drugs), or&#xD;
             immunostimulants (e.g., interferon, interleukin-2).&#xD;
&#xD;
          -  Active autoimmune disease, immunodeficiency, or history thereof (e.g., myasthenia&#xD;
             gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid&#xD;
             arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener's&#xD;
             granulomatosis, Sjogren's syndrome, Guillain-Barré syndrome, multiple sclerosis,&#xD;
             etc.). However, the following are inclusible. Patients with autoimmune hypothyroidism&#xD;
             who are using a stable dose of thyroid hormone preparations. Patients with eczema,&#xD;
             psoriasis, lichen simplex chronicus, or vitiligo vulgaris whose symptoms are limited&#xD;
             to the skin, and whose rash accounts for less than 10% of the body surface area and is&#xD;
             well controlled by topical application of low potency corticosteroids alone. No acute&#xD;
             exacerbation of the underlying disease requiring solaren long-wavelength ultraviolet&#xD;
             therapy, methotrexate, retinoids, biologics, oral calcineurin inhibitors, high potency&#xD;
             or oral corticosteroids within the past 12 months.&#xD;
&#xD;
          -  Patients who have received a live attenuated vaccine within 4 weeks prior to&#xD;
             enrollment or are expected to require a live attenuated vaccine within 5 months of&#xD;
             completion of protocol treatment.&#xD;
&#xD;
          -  Patients have not recovered from clinically significant toxicity caused by previous&#xD;
             therapy, except for alopecia and Grade 1 peripheral neuropathy.&#xD;
&#xD;
          -  Hypersensitivity or contraindication to any component of the therapeutic agent,&#xD;
             including macrogol glycerol ricinoleate (Cremophor®), an additive to paclitaxel.&#xD;
&#xD;
          -  Positive for HIV antibodies, HBs antigen, or HCV antibodies (however, if HCV&#xD;
             antibodies are positive but HCV-RNA is not detected, it is not excluded).&#xD;
&#xD;
          -  Negative for HBs antigen, positive for HBs antibody or HBc antibody, and positive for&#xD;
             HBV-DNA quantification.&#xD;
&#xD;
          -  Women who are pregnant, lactating, or may be pregnant.&#xD;
&#xD;
          -  Patients with psychosis or psychiatric symptoms that interfere with daily life and are&#xD;
             judged to be difficult to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fumikata Hara</last_name>
    <phone>+81-3-3520-0111</phone>
    <email>prj-jcog1919e-core@eps.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2021</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Japanese Foundation for Cancer Research</investigator_affiliation>
    <investigator_full_name>Fumikata Hara</investigator_full_name>
    <investigator_title>M.D., Ph.D. Chief, Breast Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

